Gastrointestinal Cancer

Malignancies that affect the digestive tract’s different component sites are classified as gastrointestinal cancers. Including esophageal, gastric, bile duct, liver, pancreatic and colorectal cancer.

Latest Videos

View all videos

KEYNOTE-177 & Checkmate142: checkpoint blockade in MSI-H/dMMR CRC

Heinz-Josef Lenz • 16 Jan 2021

Improving diversity in clinical trial enrollment

Lola A. Fashoyin-Aje • 15 Jan 2021

RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab in MSI/dMMR mCRC

Romain Cohen • 15 Jan 2021

Real-world safety of second-line 5-FU regimens in mPDAC

Zev A. Wainberg • 15 Jan 2021

Colorectal Cancer

KEYNOTE-177 & Checkmate142: checkpoint blockade in MSI-H/dMMR CRC

Heinz-Josef Lenz • 16 Jan 2021

90Y-FF-21101: a P-cadherin-targeting antibody in advanced CRC

Vivek Subbiah • 11 Jan 2021

Liver Cancer

KEYNOTE-240: pembrolizumab in advanced HCC

Philippe Merle • 14 Jan 2021

FDA considerations for approval of therapies in GI cancers

Lola A. Fashoyin-Aje • 15 Jan 2021

Bile Duct Cancer

LY3410738: a first-in-class covalent inhibitor of mutant IDH1 in CCA

Rachna T. Shroff • 7 Jan 2021

Gender representation in authorship in later-phase clinical trials in BTC

Rachna T. Shroff • 7 Jan 2021

Gastric Cancer

FIGHT: bemarituzumab + mFOLFOX6 in first-line advanced gastric cancer

Zev A. Wainberg • 15 Jan 2021

Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer

Yelena Y. Janjigian • 11 Jan 2021

Pancreatic Cancer

Real-world safety of second-line 5-FU regimens in mPDAC

Zev A. Wainberg • 15 Jan 2021

90Y-FF-21101: a P-cadherin-targeting antibody in advanced CRC

Vivek Subbiah • 11 Jan 2021

Esophageal Cancer

Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer

Yelena Y. Janjigian • 11 Jan 2021

Nivolumab for perioperative esophageal and gastroesophageal cancer: CheckMate-577

Elizabeth C. Smyth • 22 Sep 2020